Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Healthcare Policy topic
No spam. Unsubscribe anytime.
Senate passes bill to limit 340B contract pharmacy limits, empowers AG to investigate manufacturers
Summary
The Kansas Senate passed a bill intended to prevent drug manufacturers from limiting safety-net providers to a single contract pharmacy under the federal 340B program and to give the state attorney general enforcement authority over those arrangements.
Senate Bill 284, described on the floor as designed to preserve the intent of the federal 340B drug-pricing program, passed the Kansas Senate after extended committee and floor discussion.
What the bill does: SB 284 seeks to ensure covered entities — especially safety-net hospitals, critical-access hospitals and federally qualified health centers (FQHCs) — can access discounted drugs at the pharmacy of their choice, including independent pharmacies. It would prohibit manufacturers from insisting covered entities use a single contract pharmacy to dispense 340B drugs. The bill also includes enforcement authority for the Kansas Attorney General and provides a mechanism to address data-request practices manufacturers were using that committee testimony described as excessive.
Why it matters: Proponents argued manufacturers’ contract restrictions undercut the 340B program’s purpose (to stretch federal resources for uninsured and underinsured patients) and threaten rural hospitals and independent pharmacies that rely on 340B revenue or contracting. Opponents said the bill risks litigation and could shift costs to private payers and employer-sponsored insurance through higher prices or margin changes. The Kansas Board of Pharmacy noted potential staffing/fiscal effects for enforcement.
Outcome and next steps: The Senate passed the bill and it will move through the reconciliation/enrollment process, and conferees were appointed for other measures where House and Senate positions differ. Supporters urged quick enactment to protect rural hospital finances and local pharmacy access; opponents urged careful vetting to avoid unintended consequences to insurance markets.
Implementation note: Committee testimony included estimates of administrative costs for oversight (Board of Pharmacy, Attorney General) and a request that the state provide authority and capacity to enforce prohibitions against manufacturer-imposed contract limitations.
